Drug Profile
Fosravuconazole - Seren Pharmaceuticals
Alternative Names: BFE-1224; BMS-379224; E-1224; Fosravuconazole L-lysine ethanolate; NAILIN; Ravuconazole prodrug - EisaiLatest Information Update: 03 Apr 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Drugs for Neglected Diseases Initiative Foundation; Eisai Co Ltd; Seren Pharmaceuticals
- Class Antifungals; Antiprotozoals; Benzonitrile; Fluorobenzenes; Small molecules; Thiazoles; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Onychomycosis
- Phase II/III Dermatomycoses
- Phase II Chagas disease
- Discontinued Mycoses
Most Recent Events
- 30 Mar 2023 Eisai in collaboration with DNDi and the University of Khartoum completes a phase II trial in Dermatomycoses in Sudan, before March 2023 (NCT03086226)
- 14 Nov 2022 Phase-II/III clinical trials in Dermatomycoses in Sudan (PO) (Eisai pipeline, November 2022)
- 16 Apr 2021 Fosravuconazole is still in phase-II clinical trials for Chagas' disease (Combination therapy) in Bolivia